Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa

Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie; Bangsberg, David R.
September 2013
PLoS Medicine;Sep2013, Vol. 10 Issue 9, p1
Academic Journal
: Jessica Haberer and colleagues investigate the association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial. Please see later in the article for the Editors' Summary


Related Articles

  • Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. Wilton, James; Senn, Heather; Sharma, Malika; Tan, Darrell H. S. // HIV/AIDS - Research & Palliative Care;2015, Vol. 7, p125 

    Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals...

  • Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Hurt, Christopher B.; Eron Jr., Joseph J.; Cohen, Myron S. // Clinical Infectious Diseases;12/15/2011, Vol. 53 Issue 12, p1265 

    Pre-exposure prophylaxis (PrEP), the use of antiretrovirals (ARVs) by human immunodeficiency virus (HIV)- uninfected individuals to prevent acquisition of the virus during high-risk sexual encounters, enjoyed its first 2 major successes with the Centre for the AIDS Programme of Research in South...

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D...

  • A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. Corneli, Amy L.; McKenna, Kevin; Headley, Jennifer; Ahmed, Khatija; Odhiambo, Jacob; Skhosana, Joseph; Meng Wang; Agot, Kawango // Journal of the International AIDS Society;2014 Supplement 2, Vol. 17 Issue Supp 2, p1 

    Introduction: Risk perception is a core construct in many behaviour change theories in public health. Individuals who believe they are at risk of acquiring an illness may be more likely to engage in behaviours to reduce that risk; those who do not feel at risk may be unlikely to engage in risk...

  • No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. Marcus, Julia L.; Glidden, David V.; Mayer, Kenneth H.; Liu, Albert Y.; Buchbinder, Susan P.; Amico, K. Rivet; McMahan, Vanessa; Kallas, Esper Georges; Montoya-Herrera, Orlando; Pilotto, Jose; Grant, Robert M. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We...

  • Letter from the Executive Director. Caldwell, Katy // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p3 

    An introduction is presented in which the author discusses various reports within the issue including one about adherence to Truvada as pre-exposure prophylaxis (PrEP), another one about a PrEP trial in gay and bisexual men and transgender women, and one about integrating PrEP into practice.

  • Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study. Gupta, Samir K.; Shen, Changyu; Moe, Sharon M.; Kamendulis, Lisa M.; Goldman, Mitchell; Graham, Susan Marie; Dubé, Michael P. // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Objective: Changes in endothelial function, measured as flow-mediated dilation (FMD) of the brachial artery, has not been systematically assessed beyond 6 months of initiation of antiretroviral therapy (ART) when drug-related effects might offset initial improvements with virologic control....

  • Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz. McColl, Damian J.; Margot, Nicolas; Chen, Shan-Shan; Harris, Jeanette; Borroto-Esoda, Katyna; Miller, Michael D. // HIV Clinical Trials;Mar/Apr2011, Vol. 12 Issue 2, p61 

    Purpose: To compare the development of the M184V/I substitution among antiretroviral treatment-naïve patients taking the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) or lamivudine (3TC) from three phase 3 clinical trials of dual NRTIs (including either FTC or 3TC)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics